中国医科大学健康科学研究院
Institute of Health Sciences, CMU



吴安华PI课题组

吴安华 教授

二级教授、博士生导师

长江学者特聘教授

团队负责人吴安华教授，从事神经外科工作20余年，曾荣获“长江学者特聘教授”、“国家万人计划科技创新领军人才”、“国家有突出贡献中青年专家”、“教育部新世纪优秀人才”、“国务院有特殊贡献专家"等称号，同时任中华医学会神经外科分会委员、中国医师协会神经外科分会常委、辽宁省医学会神经外科学分会主任委员等职务。团队在吴安华教授的带领下，长期致力于神经系统疾病相关基础研究及神经肿瘤诊疗新技术的创新与推广应用，牵头建立科技部唯一的神经肿瘤领域创新团队，获批辽宁省脑疾病与脑科学重点实验室与沈阳市重大疾病临床研究中心。主持国家自然科学基金及省部级课题近20项，以第一作者或通讯作者发表SCI论文70余篇，包括Clinical Cancer Research、Neurology、神经肿瘤领域IF最高杂志Neuro-Oncology等知名期刊；获得实用新型专利授权3项、发明专利授权2项。研究成果入编胶质瘤国际指南1部、国内指南4部，被国外145部专著引用；主译神经肿瘤专著1部（《神经肿瘤学：原理与实践》）。以第一完成人获得教育部科技进步一等奖、辽宁省科技进步一等奖及辽宁医学科技一等奖等多项奖励。

课题组成员

教授：吴安华、程鹏

副教授：程文

讲师：朱晨

助教：沈帅，金治中

科研方向

主要从事以胶质瘤免疫治疗为主线的神经系统肿瘤综合防治研究，具体包括胶质瘤个体化临床评估体系的建立、神经系统肿瘤微环境特征解析与调控、脑肿瘤的精准防治研究、脑疾病神经认知功能障碍的机理研究等

主要学术贡献

a. 从免疫风险角度完善了胶质瘤临床评估体系，证实异常的免疫反应及免疫微环境组分是导致胶质瘤恶性临床表现的重要因素，提出胶质瘤领域首个免疫反应评价方法，开发首个针对中国人群的胶质瘤生存预测系统。

b. 优化了胶质瘤免疫治疗策略，提出导致免疫治疗抵抗的胶质瘤免疫细胞拟态学说，建立更为高效的DC瘤苗致敏方法，发现并完善以干扰素和LPS为基础的胶质瘤干细胞免疫疗法。

c. 创建以免疫学研究为重心的胶质瘤综合创新平台，共同发起亚洲最大的胶质瘤生物样本信息库“中国胶质瘤基因组图谱计划”，并正积极牵头筹建中国医科大学脑计划研究平台，推动辽宁省脑科学研究进步。

代表性论文

1. Zhang Q, Guan G, Cheng P, Cheng W, Yang L, Wu A. (2021) Characterization of an endoplasmic reticulum stress-related signature to evaluate immune features and predict prognosis in glioma. J Cell Mol Med. 2021 Feb 21.

2. Jin Z, Li X, Zhang X, Paul D, Xu T, Wu A. (2020) Engineering the fate and function of human T-cells via 3D bioprinting. Biofabrication. 2020 Dec 21.

3. Guo S, Gao W, Cheng W, Liang C, Wu A. (2020) Endoscope-Assisted Surgery vs. Burr-Hole Craniostomy for the Treatment of Chronic Subdural Hematoma: A Systemic Review and Meta-Analysis. Front Neurol. 2020 Nov 5;11:540911.

4. Shen S, Yan Z, Wu J, Liu X, Guan G, Zou C, Guo Q, Zhu C, Liu T, Chen C, Chen L, Cheng P, Cheng W, Wu A. (2020) Characterization of ROS Metabolic Equilibrium Reclassifies Pan-Cancer Samples and Guides Pathway Targeting Therapy. Front Oncol. 2020 Oct 20;10:581197.

5. Zhang Q, Yang L, Guan G, Cheng P, Cheng W, Wu A. (2020) LOXL2 Upregulation in Gliomas Drives Tumorigenicity by Activating Autophagy to Promote TMZ Resistance and Trigger EMT. Front Oncol. 2020 Oct 29;10:569584.

6. Lu WC, Xie H, Yuan C, Li JJ, Li ZY, Wu AH. (2020) Identification of potential biomarkers and candidate small molecule drugs in glioblastoma. Cancer Cell Int. 2020 Aug 28;20:419.

7. Lu WC, Xie H, Yuan C, Li JJ, Li ZY, Wu AH. (2020) Genomic landscape of the immune microenvironments of brain metastases in breast cancer. J Transl Med. 2020 Aug 31;18(1):327.

8. Zhang LY, Guo Q, Guan GF, Cheng W, Cheng P, Wu AH. (2019) Integrin Beta 5 Is a Prognostic Biomarker and Potential Therapeutic Target in Glioblastoma. Front Oncol. 2019 Sep 20;9:904.

9. Zhu C, Zou C, Guan G, Guo Q, Yan Z, Liu T, Shen S, Xu X, Chen C, Lin Z, Cheng W, Wu A. (2019) Development and

validation of an interferon signature predicting prognosis and treatment response for glioblastoma. Oncoimmunology. 2019 Jun 12;8(9):e1621677.

10. Guo Q, Guan GF, Cheng W, Zou CY, Zhu C, Cheng P, Wu AH. (2019) Integrated profiling identifies caveolae-associated protein 1 as a prognostic biomarker of malignancy in glioblastoma patients. CNS Neurosci Ther. 2019 Mar;25(3):343-354.

11. Zou CY, Guan GF, Zhu C, Liu TQ, Guo Q, Cheng W, Wu AH. (2019) Costimulatory checkpoint SLAMF8 is an independent prognosis factor in glioma. CNS Neurosci Ther. 2019 Mar;25(3):333-342.

12. Jiang Y, Han S, Cheng W, Wang Z, Wu A. (2017) NFAT1-regulated IL6 signalling contributes to aggressive phenotypes of glioma. Cell Commun Signal. 2017 Dec 19;15(1):54.

13. Zhang C, Cheng W, Ren X, Wang Z, Liu X, Li G, Han S, Jiang T, Wu A. (2017) Tumor Purity as an Underlying Key Factor in Glioma. Clin Cancer Res. 2017 Oct 15;23(20):6279-6291.

14. Han S, Wang C, Qin X, Xia J, Wu A. (2017) LPS alters the immuno-phenotype of glioma and glioma stem-like cells and induces in vivo antitumor immunity via TLR4. J Exp Clin Cancer Res. 2017 Jun 22;36(1):83.

15. Han S, Deng J, Wang Z, Liu H, Cheng W, Wu A. (2017) Decreased human leukocyte antigen A*02:01 frequency is associated with risk of glioma and existence of human cytomegalovirus: a case-control study in Northern China. Cancer Immunol Immunother. 2017 Oct;66(10):1265-1273.

16. Han S, Meng L, Jiang Y, Cheng W, Tie X, Xia J, Wu A. (2017) Lithium enhances the antitumour effect of temozolomide against TP53 wild-type glioblastoma cells via NFAT1/FasL signalling. Br J Cancer. 2017 May 9;116(10):1302-1311.

17. Cheng W, Zhang C, Ren X, Wang Z, Liu X, Han S, Wu A. (2017) Treatment strategy and IDH status improve nomogram validity in newly diagnosed GBM patients. Neuro Oncol. 2017 May 1;19(5):736-738.

18. Cheng W, Ren X, Zhang C, Cai J, Han S, Wu A. (2017) Gene Expression Profiling Stratifies IDH1-Mutant Glioma with

Distinct Prognoses. Mol Neurobiol. 2017 Oct;54(8):5996-6005.

19. Cheng W, Ren X, Zhang C, Cai J, Liu Y, Han S, Wu A. (2016) Bioinformatic profiling identifies an immune-related risk signature for glioblastoma. Neurology. 2016 Jun 14;86(24):2226-34.

20. Cheng W, Zhang C, Ren X, Jiang Y, Han S, Liu Y, Cai J, Li M, Wang K, Liu Y, Hu H, Li Q, Yang P, Bao Z, Wu A. (2017) Bioinformatic analyses reveal a distinct Notch activation induced by STAT3 phosphorylation in the mesenchymal subtype of glioblastoma. J Neurosurg. 2017 Jan;126(1):249-259.

21. Cheng P, Wang J, Waghmare I, Sartini S, Coviello V, Zhang Z, Kim SH, Mohyeldin A, Pavlyukov MS, Minata M, Valentim CL, Chhipa RR, Bhat KP, Dasgupta B, La Motta C, Kango-Singh M, Nakano I. (2016) FOXD1-ALDH1A3 Signaling Is a Determinant for the Self-Renewal and Tumorigenicity of Mesenchymal Glioma Stem Cells. Cancer Res 2016 Dec 15;76(24):7219-7230.

中国医科大学健康科学研究院 | 中国・辽宁省沈阳市沈北新区蒲河路77号 | 110122

联系我们： | 传真：

未经许可不得擅自转载本网站图文资料